← Leaderboards
Muna I Naash
University Of Houston
$18,005,875
Attributed
$21,728,249
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,728,249 · 11
By mechanism
R01$19,659,922 · 5
R21$858,000 · 2
R56$833,287 · 2
R03$289,557 · 1
P30$87,483 · 1
Top collaborators
- Muayyad R Al-Ubaidi15 shared
- Gwenaelle S Geleoc1 shared
Most similar at University Of Houston
Same institution · by research overlap
- Muayyad R Al-Ubaidi$6,623,740
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypePhotoreceptorsGenesMouse ModelToxic EffectCellsMolecularRetinaProteinsRetinitis PigmentosaRetinal DiseasesMutationStructureRetinal DegenerationStructure Of Retinal Pigment EpitheliumDefectTraffickingAffectLeadBiochemicalPlayBlindnessEffective TherapyTissues
Grant awards (60)
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$605,791
R01 · FY2025 · EY · contact PI
Mutation-independent therapy for retinal degenerations caused by PRPH2 mutations$431,750
R21 · FY2025 · EY
Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A.$400,787
R01 · FY2025 · EY · contact PI
Admin Supplement: Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A$79,344
R01 · FY2025 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$508,598
R01 · FY2024 · EY · contact PI
Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A.$400,787
R01 · FY2024 · EY · contact PI
Vector engineering for non-viral delivery of large genomic DNA to the RPE$193,750
R21 · FY2024 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$508,598
R01 · FY2023 · EY · contact PI
Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A.$400,787
R01 · FY2023 · EY · contact PI
Vector engineering for non-viral delivery of large genomic DNA to the RPE$232,500
R21 · FY2023 · EY · contact PI
Supplement for: Mechanism of Photoreceptor Cell Degeneration in Animal Models of Retinal Diseases$114,651
R01 · FY2023 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$497,608
R01 · FY2022 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$548,089
R01 · FY2021 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$497,607
R01 · FY2021 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$565,038
R01 · FY2020 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$539,089
R01 · FY2020 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$565,038
R01 · FY2019 · EY · contact PI
Role of retbindin in retinal homeostasis and diseases$382,500
R01 · FY2019 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal disease$376,250
R01 · FY2019 · EY · contact PI
Gene Therapy of Usher Syndrome$354,000
R56 · FY2019 · DC
Compacted DNA Nanoparticles for Ocular Therapy$565,038
R01 · FY2018 · EY · contact PI
Role of retbindin in retinal homeostasis and diseases$382,500
R01 · FY2018 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal disease$376,250
R01 · FY2018 · EY · contact PI
Role of retbindin in retinal homeostasis and diseases$378,854
R01 · FY2017 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal disease$376,250
R01 · FY2017 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal disease$376,250
R01 · FY2016 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$376,250
R01 · FY2016 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal disease$420,000
R01 · FY2015 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$212,013
R01 · FY2015 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$150,587
R01 · FY2015 · EY · contact PI
DNA nanoparticle formulations for optimal ocular gene delivery$400,278
R01 · FY2014 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$362,600
R01 · FY2014 · EY · contact PI
DNA nanoparticle formulations for optimal ocular gene delivery$424,140
R01 · FY2013 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$370,000
R01 · FY2013 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$523,943
R01 · FY2012 · EY · contact PI
DNA nanoparticle formulations for optimal ocular gene delivery$431,877
R01 · FY2012 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$351,600
R01 · FY2012 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$495,259
R01 · FY2011 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$351,600
R01 · FY2011 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$498,048
R01 · FY2010 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$362,588
R01 · FY2010 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$68,224
R01 · FY2010 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$499,907
R01 · FY2009 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$366,250
R01 · FY2009 · EY · contact PI
Mechanism of photoreceptor cell degeneration in animal models of retinal diseases$479,287
R56 · FY2008 · EY · contact PI
Compacted DNA Nanoparticles for Ocular Therapy$366,250
R01 · FY2008 · EY · contact PI
Mechanism of photoreceptor cell degeneration$492,695
R01 · FY2007 · EY · contact PI
Mechanism of photoreceptor cell degeneration$481,035
R01 · FY2006 · EY · contact PI
Sustained, Non-viral Ocular Therapy Using Nanoparticles$143,057
R03 · FY2006 · EY · contact PI
Mechanism of photoreceptor cell degeneration$478,263
R01 · FY2005 · EY
Sustained, Non-viral Ocular Therapy Using Nanoparticles$146,500
R03 · FY2005 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$535,962
R01 · FY2003 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$363,383
R01 · FY2002 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$118,640
R01 · FY2002 · EY
CORE--IMAGING AND STRUCTURAL ANALYSIS MODULE$0
P30 · FY2002 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$352,799
R01 · FY2001 · EY
CORE--IMAGING AND STRUCTURAL ANALYSIS MODULE$0
P30 · FY2001 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$203,587
R01 · FY2000 · EY
MECHANISMS OF PHOTORECEPTOR CELL DEGENERATION$156,440
R01 · FY2000 · EY
CORE--IMAGING AND STRUCTURAL ANALYSIS MODULE$87,483
P30 · FY2000 · EY